BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:As immuno-oncology drug development transforms cancer treatmen
 t paradigms\, preclinical and clinical data continues to demonstrate that
  the TIGIT axis blockade\, particularly in combination with other immune 
 checkpoint inhibitor partners\, has strong efficacy. Despite recent clini
 cal setbacks\, and with at least 15 anti-TIGIT axis drugs in active clini
 cal development\, TIGIT axis targeting remains a promising treatment appr
 oach.\n\nIn the context of a need to accelerate practice-changing cancer 
 immunotherapies towards approval and to patients in need\, the 3rd TIGIT 
 Axis Therapies Summit returns to reunite large pharma\, innovative biotec
 hs and pioneering academics to discuss the full range of next-generation 
 TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in 
 the solid tumor\, blood cancer and non-oncology setting.\n\nCovering deci
 phering the mechanistic intricacies underlying TIGIT axis signaling\, def
 ining combination partners that improve efficacy and strengthen TIGIT tar
 geted pipelines\, exploring novel drug designs in terms of Fc functionali
 ty and IgG type\, identifying molecular signatures relevant to the tumor 
 microenvironment and periphery to incorporating unique pharmacology prope
 rties into trial design\, this is your comprehensive guide for addressing
  the unique challenges of TIGIT axis targeted drug development and poweri
 ng up your pipelines.\n\nThis year's sharp two-day agenda leans into the 
 clinical headwinds faced by so many immune checkpoint targets. As the spa
 ce regroups\, join the conversation to build meaningful partnerships and 
 maximize the clinical and commercial success of the next generation of TI
 GIT axis targeted drugs.\n\nEarlybird and team discounts available!\n\nUR
 Ls:Tickets: https://go.evvnt.com/1234464-2?pid=185Brochure: https://go.ev
 vnt.com/1234464-3?pid=185\n\nPrices:Conference Only - Industry Pricing - 
 On the Day : USD 2299.00\,Conference Only - Academic Pricing - On the Day
 : USD 2099.00\,Conference Only - Service and Solution Provider Pricing - 
 On the Day: USD 2799.00\n\nSpeakers: Murali Ramachandra\, Chief Executive
  Officer\, &nbsp\;Aurigene Discovery Technologies\, David Wald\, Associat
 e Professor\, Case Western Reserve University\, Leonie Meima\, Vice Presi
 dent Business Development\, Coherus Biosciences\, Eran Ophir\, Senior Vic
 e President Research and Drug Discovery\, Compugen\, William Freed-Pastor
 \, Instructor of Medicine\, Dana-Farber Cancer Institute and Harvard Medi
 cal School\, Namrata Patil\, Principal Scientist\, Genentech\, Gregory Dr
 iessens\, Program Leader\, iTeos Therapeutics\, Sandhya Girish\, Vice Pre
 sident Clinical Pharmacology\, Gilead Sciences\, Farahnaz Forozan\, Presi
 dent\, Forozan OncoGen Consulting\, Suba Krishnan\, Senior Vice President
 \, Clinical Development\, Mereo BioPharma\, Alon Vitenstein\, Senior Scie
 ntist\, Nectin Therapeutics\, Keren Paz\, Chief Development Officer\, Nec
 tin Therapeutics\, Pini Tsukerman\, Chief Scientific Officer\, Nectin The
 rapeutics\, Anil Thotakura\, Head of Immuno-Oncology\, Orion Corporation\
 , George Fromm\, Vice President of Research and Development\, Shattuck La
 bs\, Nicole Joller\, &nbsp\;Associate Professor\, University of Zurich\, 
 Tobias Bald\, Group Leader of the Tumor Immuno-Biology Lab\, University H
 ospital Bonn\, Alicja Copik\, Associate Professor of Medicine\, Universit
 y of Central Florida\, Walter Fiedler\, Associate Professor\, University 
 Medical Center Hamburg-Eppendorf\, Franziska Brauneck\, Assistant Physici
 an\, University Medical Center Hamburg-Eppendorf\, Shannon M Ruppert\, Se
 nior Scientist\, Genentech\, Tae Hyun Hwang\, Endowed Chair\, Mayo Clinic
 \n\nVenue details: Virtual Event\, United States\n
DTEND:20221208T170000
DTSTAMP:20260512T213553Z
DTSTART:20221207T080000
LOCATION:Virtual Event\, Suffolk County\, 02108\,
SEQUENCE:0
SUMMARY:As immuno-oncology drug development transforms cancer treatment pa
 radigms\, preclinical and clinical data continues to demonstrate that the
  TIGIT ax...
UID:6e90d973-e984-4968-93c2-f91e2c376c29
END:VEVENT
END:VCALENDAR